SEC Tracker
Get the app

Kymera Therapeutics KYMR

Atlas Venture Opportunity Fund I (Shareholder) plans to sell 8,882 KYMR shares, about $386,278

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Mar 11, 2024
  2. Broker: Merrill
  3. Shares acquired by: Private Placement
  4. 10b5-1 plan adopted: Jan 22, 2024

All of Atlas Venture Opportunity Fund I's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 5,122 shares at $43.42 on Mar 11, 2024 · Form 4
  • Sold 1,045 shares at $43.42 on Mar 11, 2024 · Form 4
  • Sold 1,819 shares at $42.52 on Mar 12, 2024 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Kymera Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Acadia Pharmaceuticals ACAD public float $2.3B, Jun 30, 2025
  2. Twist Bioscience TWST public float $2.3B, Mar 31, 2025, over 18 months old
  3. Xenon Pharmaceuticals XENE public float $2.4B, Jun 30, 2025
  4. Summit Therapeutics SMMT public float $2.5B, Jun 30, 2025
  5. Cytokinetics CYTK public float $2.5B, Jun 30, 2025